Indian regulator seeks clarification on Lantus's cancer link
This article was originally published in Scrip
Executive Summary
India's regulator, the drugs controller general of India (DCGI), is seeking a clarification from Sanofi-Aventis on its long-acting (once-daily) insulin analogue, Lantus (insulin glargine).